Hookipa Pharma Inc.

05/20/2021 | Press release | Distributed by Public on 05/20/2021 05:04

HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO